The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Headline
As the nation celebrates National Nurses Week in the midst of the COVID-19 pandemic, nurses' commitment and strength is inspiring communities across the…
Headline
The American Organization for Nursing Leadership yesterday unveiled a new resource to provide nurse leaders with practical tips and effective strategies for…
Headline
This year was already designated as the International Year of the Nurse and the Midwife before our current pandemic re-emphasized nurses’ vital role in caring…
Blog
When the World Health Assembly designated 2020 as the International Year of the Nurse and the Midwife, they had no idea a pandemic would envelop the world the…
Insights and Analysis
Rising to the Nightingale Challenge: Empowering the Next Generation of Health Care Trailblazers Nurses are the engine of health care. There are more…
Headline
AHA and its American Organization for Nursing Leadership today voiced support for the Resolving Extended Limbo for Immigrant Employees and Families Act (S.…